[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100652479":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":49,"collaborators":19,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":19,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":19,"studyType":66,"phases":67,"briefSummary":70,"conditions":71,"keywords":73,"overallStatus":29,"whyStopped":19,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"The University of Hong Kong-Shenzhen Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"SFRT arm","EXPERIMENTAL","Adding spatially fractionated radiotherapy (SFRT) to standard-of-care treatment.",[13],"Radiation: spatially fractionated radiotherapy",[15],{"type":16,"name":17,"description":17,"armGroupLabels":18,"otherNames":19},"RADIATION","spatially fractionated radiotherapy",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Zhiyuan Xu, MD","CONTACT","+86 0755-86913333","xuzy@hku-szh.org",[27],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"The University of Hong Kong - Shenzhen Hospital","RECRUITING","Shenzhen","Guangdong","518053","China","CN",{"type":36,"coordinates":37},"Point",[38,39],114.0683,22.54554,{"lat":39,"lon":38},[42,44,47],{"name":22,"role":23,"phone":43,"phoneExt":19,"email":25},"18307555170",{"name":45,"role":23,"phone":24,"phoneExt":19,"email":46},"Yang Li, MD","yangl1@hku-szh.org",{"name":22,"role":48,"phone":19,"phoneExt":19,"email":19},"PRINCIPAL_INVESTIGATOR",{"type":50,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"SPONSOR_INVESTIGATOR","Xu Zhi-yuan","Chief Physician","100652479","phase-1-spatially-fractionated-radiotherapy-for-tumor-treatment-100652479",false,"NCT07774819","Spatially Fractionated Radiotherapy for Tumor Treatment","Spatially Fractionated Radiotherapy for Bulky or Refractory Solid Tumors: Efficacy and Toxicity","Inclusion Criteria:\n\n* Patients with a bulky solid tumor with a maximum diameter \\>4 cm or a refractory solid tumor.\n\nExclusion Criteria:\n\n* Tumors involving hollow viscera that are considered to have a clinically significant risk of bleeding or perforation.\n* Patients with impaired consciousness or who are unable to care for themselves.","ALL","18 Years","75 Years",{"count":64,"type":65},126,"ESTIMATED","INTERVENTIONAL",[68,69],"PHASE1","PHASE2","To explore the efficacy and toxicity of spatially fractionated radiotherapy in the treatment of tumors.",[72],"Radiotherapy-Induced Immune Priming",[74,75],"Spatially fractionated radiotherapy","Bulky tumor","2026-08-17",{"date":78,"type":79},"2026-08-19","ACTUAL",{"date":81,"type":79},"2024-12-19",{"date":83,"type":65},"2028-12",{"name":51,"class":6},1]